Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03235245
Title Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors European Organisation for Research and Treatment of Cancer - EORTC

skin melanoma

mucosal melanoma


Binimetinib + Encorafenib

Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | BEL

Additional content available in CKB BOOST